Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
BI 2536 in elderly relapsed/refractory AML
NCT00701766Phase 2Completed
- Sponsor
- Boehringer Ingelheim
- Start
- Oct 2006
- Primary completion
- Oct 2009
- Modality
- Small Molecules
- Countries
- 2
01
Overview
A Phase 2 trial of BI-2536 in acute myeloid leukemia (AML), sponsored by Boehringer Ingelheim. Started Oct 2006; status: completed.
02
Drugs
BI-2536
03
Conditions
acute myeloid leukemia (AML)
Beyond the preview
Go deeper on NCT00701766.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00701766.